{"id":25472,"date":"2022-09-23T00:30:00","date_gmt":"2022-09-22T16:30:00","guid":{"rendered":"https:\/\/flcube.com\/?p=25472"},"modified":"2025-02-05T00:36:31","modified_gmt":"2025-02-04T16:36:31","slug":"sino-biopharmaceutical-licenses-lanifibranor-for-nash-treatment-from-inventiva","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25472","title":{"rendered":"Sino Biopharmaceutical Licenses Lanifibranor for NASH Treatment from Inventiva"},"content":{"rendered":"\n<p>China-based Sino Biopharmaceutical Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>) has announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd (CTTQ), has entered into a licensing agreement with France-headquartered Inventiva (<a href=\"https:\/\/www.google.com\/finance\/quote\/IVA:NASDAQ\">NASDAQ: IVA<\/a>). The deal grants CTTQ development, manufacturing, and commercialization rights to lanifibranor, Inventiva\u2019s drug for the treatment of nonalcoholic steatohepatitis (NASH) and potentially other metabolic disease indications in mainland China, Hong Kong, Macau, and Taiwan.<\/p>\n\n\n\n<p><strong>Financial Terms of the Agreement<\/strong><br>Under the terms of the agreement, CTTQ will pay Inventiva an upfront payment of $12 million, with an additional $5 million contingent on the achievement of certain clinical milestones. Inventiva has the potential to receive up to $290 million in clinical, regulatory, and commercial milestone payments. Additionally, subject to regulatory approval, Inventiva will receive tiered royalties ranging from high single-digit to mid-teen double digits of net sales made by Sino Biopharmaceutical in Greater China during the first three years of commercialization, and from low to mid-teen double digits starting from year four.<\/p>\n\n\n\n<p><strong>Drug Overview and Mechanism<\/strong><br>Lanifibranor is a PPAR agonist designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPAR\u03b1 and PPAR\u03b4, and a partial activation of PPAR\u03b3. Unlike other PPAR agonists that target only one or two PPAR isoforms, lanifibranor is the most advanced pan-PPAR agonist in clinical development for the treatment of NASH.<\/p>\n\n\n\n<p><strong>Future Outlook<\/strong><br>The licensing agreement between CTTQ and Inventiva marks a significant step in expanding access to innovative treatments for NASH in Greater China. With its balanced activation of PPAR isoforms, lanifibranor has the potential to address significant unmet needs in the treatment of NASH and related metabolic diseases.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Jiangsu Chia Tai Tianqing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[661,908,3092,3546,76,313],"class_list":["post-25472","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-chia-tai-tianqing-pharmaceutical","tag-hkg-1177","tag-inventiva-s-a","tag-nasdaq-iva","tag-nash","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharmaceutical Licenses Lanifibranor for NASH Treatment from Inventiva - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd (CTTQ), has entered into a licensing agreement with France-headquartered Inventiva (NASDAQ: IVA). The deal grants CTTQ development, manufacturing, and commercialization rights to lanifibranor, Inventiva\u2019s drug for the treatment of nonalcoholic steatohepatitis (NASH) and potentially other metabolic disease indications in mainland China, Hong Kong, Macau, and Taiwan.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25472\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharmaceutical Licenses Lanifibranor for NASH Treatment from Inventiva\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25472\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-22T16:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-04T16:36:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25472#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25472\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharmaceutical Licenses Lanifibranor for NASH Treatment from Inventiva\",\"datePublished\":\"2022-09-22T16:30:00+00:00\",\"dateModified\":\"2025-02-04T16:36:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25472\"},\"wordCount\":282,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Chia Tai Tianqing Pharmaceutical\",\"HKG: 1177\",\"Inventiva S.A.\",\"NASDAQ: IVA\",\"NASH\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25472#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25472\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25472\",\"name\":\"Sino Biopharmaceutical Licenses Lanifibranor for NASH Treatment from Inventiva - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-09-22T16:30:00+00:00\",\"dateModified\":\"2025-02-04T16:36:31+00:00\",\"description\":\"China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd (CTTQ), has entered into a licensing agreement with France-headquartered Inventiva (NASDAQ: IVA). The deal grants CTTQ development, manufacturing, and commercialization rights to lanifibranor, Inventiva\u2019s drug for the treatment of nonalcoholic steatohepatitis (NASH) and potentially other metabolic disease indications in mainland China, Hong Kong, Macau, and Taiwan.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25472#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25472\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25472#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharmaceutical Licenses Lanifibranor for NASH Treatment from Inventiva\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharmaceutical Licenses Lanifibranor for NASH Treatment from Inventiva - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd (CTTQ), has entered into a licensing agreement with France-headquartered Inventiva (NASDAQ: IVA). The deal grants CTTQ development, manufacturing, and commercialization rights to lanifibranor, Inventiva\u2019s drug for the treatment of nonalcoholic steatohepatitis (NASH) and potentially other metabolic disease indications in mainland China, Hong Kong, Macau, and Taiwan.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25472","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharmaceutical Licenses Lanifibranor for NASH Treatment from Inventiva","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=25472","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-09-22T16:30:00+00:00","article_modified_time":"2025-02-04T16:36:31+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25472#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25472"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharmaceutical Licenses Lanifibranor for NASH Treatment from Inventiva","datePublished":"2022-09-22T16:30:00+00:00","dateModified":"2025-02-04T16:36:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25472"},"wordCount":282,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Chia Tai Tianqing Pharmaceutical","HKG: 1177","Inventiva S.A.","NASDAQ: IVA","NASH","Sino Biopharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25472#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25472","url":"https:\/\/flcube.com\/?p=25472","name":"Sino Biopharmaceutical Licenses Lanifibranor for NASH Treatment from Inventiva - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-09-22T16:30:00+00:00","dateModified":"2025-02-04T16:36:31+00:00","description":"China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd (CTTQ), has entered into a licensing agreement with France-headquartered Inventiva (NASDAQ: IVA). The deal grants CTTQ development, manufacturing, and commercialization rights to lanifibranor, Inventiva\u2019s drug for the treatment of nonalcoholic steatohepatitis (NASH) and potentially other metabolic disease indications in mainland China, Hong Kong, Macau, and Taiwan.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25472#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25472"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25472#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharmaceutical Licenses Lanifibranor for NASH Treatment from Inventiva"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25472"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25472\/revisions"}],"predecessor-version":[{"id":25473,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25472\/revisions\/25473"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25472"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25472"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}